Glibenclamide 5 Mg + Metformin Hydrochloride 500 Mg + Pioglitazone Hydrochloride 15 Mg

Take the tablet as prescribed by the physician. Usually taken once or twice daily with meals. Swallow the tablet with water. Follow dietary recommendations and regular physical activity for better diabetes control.

Keep out of the reach and sight of children. Do not store above 25ºC. Keep in the original package or container supplied. Do not transfer them to another container. Do not use after the expiry date that is stated on the outer packaging.

Nausea, Diarrhea, Weight gain, Headache, Hypoglycemia (low blood sugar) Fluid retention or swelling, Liver enzyme elevation, Vitamin B12 deficiency with long-term metformin use.

Do not use this drug if: Known hypersensitivity to glibenclamide, metformin, pioglitazone, or related medicines Type 1 diabetes mellitus Diabetic ketoacidosis Severe kidney or liver impairment Severe heart failure

Monitor blood glucose levels regularly. This medicine is not recommended during pregnancy as there is positive evidence of fetal risk Watch for symptoms of low blood sugar, such as sweating, dizziness, or confusion. Inform your doctor if you have liver disease, heart disease, or kidney problems. Avoid Alcohol consumption as it may increase the risk of side effects. Regular monitoring of liver function and kidney function may be required.

Panikar V, Chandalia HB, Joshi SR, et al. Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy. J Assoc Physicians India. 2003;51:1061-4. FDA Drug Label – Glyburide (Glibenclamide), DailyMed Database. Product Information: Metformin Juta oral tablet, metformin hydrochloride oral tablet. Juta Pharma GmbH (per AEMPS;Spain), Gutenbergstrasse 13, 24941 Flensburg, Germany, 2019. Glibenclamide, Pioglitazone and Metformin Hydrochloride (SR) [Product Description]. Ahmedabad, Gujarat: TORRENT PHARMACEUTICALS LTD.; 2014. [Accessed 28th Sept. 2023]

Glibenclamide stimulates insulin secretion from pancreatic β-cells by binding to the sulfonylurea receptor (SUR1) and inhibiting ATP-sensitive potassium channels, leading to depolarization and insulin release. Metformin reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity through activation of AMP-activated protein kinase (AMPK). Pioglitazone acts as a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, enhancing insulin sensitivity in adipose tissue, skeletal muscle, and liver.

Anti Diabetic